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Chaperone-mediated autophagy (CMA) selectively delivers cytosolic proteins with an exposed CMA-targeting motif
to lysosomes for degradation and plays an important role in protein quality control and cellular homeostasis. A
growing body of evidence supports the hypothesis that CMA dysfunction may be involved in the pathogenic
process of neurodegenerative diseases. Both down-regulation and compensatory up-regulation in CMA activities
have been observed in association with neurodegenerative conditions. Recent studies have revealed several new
mechanisms by which CMA function may be involved in the regulation of factors critical for neuronal viability and
homeostasis. Here, we summarize these recent advances in the understanding of the relationship between CMA
dysfunction and neurodegeneration and discuss the therapeutic potential of targeting CMA in the treatment of
neurodegenerative diseases.
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Based on delivery mechanisms of cargo destined for the ly-
sosomes, autophagy can be classified into three types,
macroautophagy, microautophagy, and chaperone-mediated
autophagy (CMA) [1]. CMA selectively delivers cytosolic
proteins with a CMA targeting motif to lysosomes for deg-
radation and plays an important role in protein quality con-
trol (QC) in cells [2-4]. Recently, a growing body of
evidence supports that dysfunction of CMA may con-
tribute to the etiologic and pathogenic process of neuro-
degenerative disease. Here, we describe recent advances in
the understanding of the relationship between CMA dys-
function and neurodegeneration.CMA: a unique machinery for cellular homeostasis
Basic components of CMA machinery
At the cellular level, CMA is a vital multi-step process.
It involves recognition of potential substrates by the
chaperone protein, heat shock cognate protein 70 (Hsc70),
delivery of substrates to lysosomes, transport of unfolded* Correspondence: zmao@emory.edu
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unless otherwise stated.substrates into lysosomes by receptor LAMP2A, and deg-
radation (Figure 1).Substrate-CMA motif protein
Generally, a typical CMA substrate protein contains a
KFERQ-like motif in its sequence which can be recog-
nized by the chaperone protein Hsc70 when exposed
and not buried in a protein fold. Two characteristics as-
sociated with this motif are notable: (1) motif plasticity:
previous analysis established that about 30% of cyto-
solic proteins contain the putative KFERQ motif in
their primary sequences [5]. Recent studies found that
post-translational modifications (PTMs) such as phos-
phorylation and acetylation can change amino acid
charge and can turn an atypical motif which differs by
one residue from the standard one into a more effect-
ive motif recognizable by the CMA process [6-8]. Al-
ternatively, a string of imperfect and overlapping motifs
can also serve to mediate the CMA process [9]. Addition-
ally, some of the KFERQ motifs in their native conditions
may be concealed by normal protein folding in the interior
of a protein, which is thought to prevent degradation via
CMA under normal, unstressed conditions. After misfold-
ing, partial unfolding, or PTMs that may influence the
recognition motif directly or allosterically, conformationalral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
















Figure 1 Steps and regulation of CMA. “X” represents local region or site of regulation.
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the respective proteins then become suitable CMA cargo
[3,10]; (2) multiple compartment sources of substrate pro-
teins: prior studies suggested that soluble cytosolic pro-
teins could be degraded by CMA [11,12]. But any proteins
which can be delivered to the cytosol from other com-
partments via cellular trafficking may be regulated by
CMA. These include plasma membrane proteins, or-
ganelle membrane proteins, or nuclear proteins [2,13].
Furthermore, it is theoretically possible that cleaved
protein fragments under various conditions can also be
degraded by CMA as long as they retain a CMA recog-
nition motif.Ambiguous chaperone-Hsc70
The cytosolic Hsc70 (cyt-Hsc70) is a multifunctional
chaperone involved in different cellular functions, in-
cluding protein refolding and targeting to different or-
ganelles [14,15]. For CMA, cyt-Hsc70 protein interacts
with substrate proteins via their CMA recognition motifs
to deliver CMA substrates to lysosomes for degradation.
In addition to lysosomes, Hsc70 can also deliver proteins
with a CMA motif to late endosomes where they undergo
degradation through endosomal microautophagy (e-MI)
[16]. However, the mechanisms that determine to where
the target proteins are delivered (CMA or e-MI) are not
clear and remain to be elucidated. A recent study has
shown that Hsc70 can bind to protein aggregates and tar-
get them to lysosomes via chaperone-assisted selective au-
tophagy (CASA) [17]. Therefore, CMA is just one of the
tasks performed by Hsc70.In addition to cyt-Hsc70, lysosome-associated Hsc70
(lys-Hsc70) localized within the lumen of lysosomes is
also involved in CMA [18]. Blockage of epitopes on lys-
Hsc70 interrupts the internalization rather than membrane
binding of CMA substrate proteins. Hence, lys-Hsc70 plays
a key role in substrate translocation after delivery to
lysosomal surface by cyt-Hsc70. Under oxidative stress
or starvation, both the amount of lys-Hsc70 in lysosomes
and the number of lysosomes with lys-Hsc70 increase re-
markably [10,19]. But whether and how pathological con-
ditions alter lys-Hsc70 remains unclear.CMA receptor-LAMP2A
The lysosome-associated membrane protein type 2a
(LAMP2A), in contrast to the other two splice vari-
ants, LAMP2B and C, is the receptor for CMA sub-
strates. The LAMP2A-mediated translocation step is
rate limiting for the whole CMA process [20]. CMA
substrate protein binds to the c-terminal cytosolic tail
of LAMP2A at the lysosomal membrane and this inter-
action quickly promotes the monomeric form of LAMP2A
to assemble into a high molecular weight complex of about
700 Kd [20,21]. Once a substrate has been released into
the lysosomal lumen, the complex dissociates into
monomers again. In fact, binding of substrate pro-
teins is restricted to monomers of LAMP2A. In con-
trast, translocation begins only after multimerization
of LAMP2A. Interestingly, Eskelinen and co-workers
found that LAMP-1 and -2 double deficiencies did not
affect CMA-mediated proteolysis in mouse embryonic fi-
broblasts, suggesting that LAMP2A may not be the only
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ceptor mechanisms for the CMA process [22].
Lysosomes: an advanced organelle
Lysosomes are ubiquitous membrane-bound intracellu-
lar organelles involved in many cellular processes and
considered to be a crucial regulator of cellular homeo-
stasis rather than waste bags [23]. As the destination for
CMA, lysosomes maintain a highly acidic pH within
their lumen in order to digest delivered contents and
then to drive efflux of digested metabolites, thereby re-
cycling key digested components. The function of lyso-
somes is critically dependent on both soluble lysosomal
hydrolases (e.g. proteases, lipases, glycosidases and nucle-
ases) and lysosomal membrane proteins (e.g. lysosome-
associated membrane proteins) [24,25].
Recent research has revealed that the transcription fac-
tor EB (TFEB) can enter the nucleus and bind to coor-
dinated lysosomal expression and regulatory (CLEAR)
elements, and induce the transcription of genes in-
volved in lysosomal biogenesis [26,27], acting as a mas-
ter regulator of lysosomal function to coordinate the
activity of the lysosomal network in response to chan-
ging environment and cellular needs [28,29]. The path-
ways that mediate the fate of the end products of
lysosomal digestion are poorly understood. Generally,
the metabolites of lysosomes, degradation end prod-
ucts, will be reused for protein synthesis or cellular
respiration in the cytosol after lysosomal efflux via diffu-
sion or transport through specific transporters (lysosomal
membrane proteins that export lysosomal degradation
products) [30-32]. However, the detailed mechanisms that
maintain the balance between degradation and recycling
processes require further investigation (Figure 1).
Regulatory mechanisms of CMA
Although the basic steps of the CMA process are
well characterized, our understanding of how CMA is
regulated is very limited. The levels of CMA activity
are believed to change constantly, allowing adaptation
to both immediate and long-term needs of the
cells. Some known regulatory mechanisms include the
following:
(1)Regulation at a molecular level: CMA activity could be
regulated by modulating substrate binding via LAMP2A
and also substrate translocation via lys-Hsc70.
Changes in LAMP2A abundance due to changes in its
synthesis, degradation, redistribution, and conformation
at the lysosomal membrane have profound effects on
CMA activity and flux [21]. Additionally, the stability of
the CMA translocation complex of LAMP2A has been
found to be modulated by a GFAP-EF1a complex [33].For lys-Hsc70, an increase in its level may lead to a
gradual augmentation of CMA activity. These mechanisms
have been reviewed in detail elsewhere [15,19,34-36].
(2)Regulation at a pathway level: CMA activity could
be regulated by modulating the equilibrium of flux
through the autophagic/proteolytic system, and the
equilibrium of influx and efflux across the lysosomal
membrane.
In cells, a proteostasis network comprised of CMA,
macrophagy (MA), and the ubiquitin-proteosome system
(UPS) exists [37]. For cellular protein and metabolite
homeostatsis, an intricate and delicate equilibrium among
these pathways needs to be maintained. Alteration of any
single pathway will precipitate changes in the other pro-
teolytic pathways. For example, CMA blockage could in-
duce MA up-regulation. On the other hand, blockage of
MA results in CMA activation [38,39]. Similarly, a de-
crease in CMA or MA activity has been found to lead to
changes in the activity of the UPS [40,41]. The molecular
mechanisms underlying the cross-talk among these differ-
ent pathways have not been fully elucidated. Yet, there is
some experimental evidence to suggest that this may also
involve lys-Hsc70 and/or LAMP2A [42]. The equilibrium
of influx and efflux transport across the lysosomal mem-
brane is poorly understood [30]. Processing a subset of
soluble cytosolic proteins by CMA will lead to the gener-
ation of a group of degradation end products for reuse. If
the end products are in shortage or excess for subsequent
synthesis of essential proteins, there should be compensa-
tory alterations in the influx and efflux processes. Some
studies have revealed that a putative amino acid efflux
transporter in lysosomes, Atg22, plays a role in autophagy.
Atg22 cooperates with two other proteins, Avt3 and Avt4,
in supporting amino acid transport [43]. However,
whether Atg22 participates in the regulation of CMA is
unknown and this and other factors that could affect the
final steps of CMA clearly require further investigation.
The roles of CMA in neurodegeneration
Given the important role of CMA in maintaining cellu-
lar homeostasis, it is not surprising that CMA dysfunc-
tion has been linked to the pathogenic processes of
severe human disorders. Because of their postmitotic na-
ture, neurons are especially sensitive to homeostatic
changes. Both down-regulation and compensatory up-
regulation of CMA activity have been shown to be asso-
ciated with neurodegeneration [7,44,45]. Interestingly,
among these studies, increasing CMA activity has only
been reported in relatively younger HD mice rather than
older mice, suggesting that there may be heterogenous
alterations of CMA between early and late stages of a
pathogenic process [45].
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neurodegeneration
Certain environmental elements, genetic variations,
and aging have all been identified as etiological fac-
tors associated with various neurodegenerative dis-
eases [46,47]. The potential role of CMA dysfunction
in neurodegenerative disease is a subject of increasing
interest. This has led to some efforts aimed at ad-
dressing the relationship between CMA and other
known etiological factors.
(1)Environmental risk factors: compared to our under-
standing of how toxins dysregulate MA machinery,
little mechanistic detail is known about the interaction
between environmental factors and CMA. Of the
few studies focusing on the effects of neurotoxins
on CMA activity, Marin and co-workers showed that
the levels of LAMP2A and Hsp90 are increased in
the nigral region in the 6-hyroxydopamine (6-OHDA)-
induced unilateral lesion rat model, providing in vivo
evidence for toxin-induced change in CMA activity
[48]. Consistently, a recent study by Gao et al. found that
6-OHDA induces an increase in LAMP2A in the sub-
stantia nigra pars compacta of mouse brain [43]. In
cellular models where experimental conditions can
be more precisely controlled, it has been shown that
limited exposure to moderate levels of insults (toxin
or stress) leads to an increase in CMA [43,49]. This
appears to represent a cellular protective response
to alleviate toxin-induced damage. But persistent expo-
sure to high levels of toxic insults has been clearly dem-Table 1 Pathogenic variants of CMA substrate protein in neuro
CMA substrate/
binding Protein








α-synuclein [51,55] Function is not well understood A30P, A53T
Leucine-rich repeat
kinase 2 (LRRK2) [59,60]
Involved in mitogen-activated
protein kinase, protein translation
control, programmed cell death,
and activity in cytoskeleton
dynamics
G2019S




A mediator of stress- and
Aβ-induced neuronal death
\




Note: \ (No reports are currently available); ↓ (Decrease); ↑ (Increase).onstrated to result in a severe decrease in CMA activity.
However, the effects of these various toxins on CMA
substrates are complex and may not always be related
directly to CMA. For example, Sala and colleagues re-
ported that the mitochondrial toxin rotenone induces
an increase in the levels of CMA substrates synu-
clein and MEF2D [50]. But the changes in these protein
levels appeared to be due to changes in the regu-
lation of their de novo synthesis rather than inhibition
of their CMA-mediated degradation.
(2)Genetic risk factors: the mutant variants of several
pathogenic proteins bearing CMA-targeting motif(s)
have been shown to impair CMA activity. These in-
clude α-synuclein, ubiquitin C-terminal hydrolase
L1 (UCH-L1), and leucine-rich repeat kinase 2 (LRRK2)
[51-53]. Aside from being more resistant to CMA
degradation, an emerging common mode of action for
several of these pathogenic variants is that they exert
negative effects on CMA via inhibiting the CMA
process at the lysosomal membrane and interfering
with the degradation of other CMA substrates. In
addition, our previous study identified that high levels
of either wild type or PD associated α-synuclein mu-
tant disrupt CMA-mediated regulation of neuronal sur-
vival factor, MEF2D, which plays a role in neuronal
stress and death [9].
(3)Aging: Studies of aged rodents and humans have
revealed that aging is associated with a decline in CMA
activity. This impairment of CMA in aging is mainly
due to a decrease in the levels of LAMP2A at the
lysosomal membrane secondary to its reduced stabilitydegenerative disease
ant Molecular mechanism Effects on CMA
activity
Disease
Abnormal binding to LAMP2A
to block degradation by
CMA substrates
↓ PD
Abnormally high affinity binding




Interference with the organization
of the CMA translocation complex
and cause defective CMA
↓ PD
n Oligomerization at the surface of
lysosomes to disrupt the membrane
integrity and blockage of normal
CMA function
↓ AD
Mechanistic effects on lysosome
unclear
↓ AD
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CMA receptor [54].
CMA substrate proteins and pathogenic roles in
neurodegenerative diseases
CMA defects implicated in the etiology of
neurodegenerative diseases
Accumulation of pathogenic CMA substrate proteins
such as α-synuclein, in the form of insoluble inclusions,
is a common hallmark underlying the degenerative process
of many diseases, such as Parkinson’s disease (PD) and cer-
tain tauopathies. CMA can only degrade the soluble forms
of these proteins. Once forming insoluble inclusions, they
are much more resistant to CMA-mediated degradation.
These aggregates may often exert a “clogging or blockage
effect” at the lysosomal membrane, thus becoming toxic by
inhibiting the CMA-mediated degradation of other cyto-
solic substrate proteins [51,55]. Although it is not clear
whether CMA dysfunction may contribute to the initial
formation of insoluble inclusions, it is quite possible that
the “blockage effect” on CMA may exacerbate the forma-
tion of inclusion bodies by increasing misfolded protein
concentrations in the cytoplasm. Despite this common
“blockage” mode of action, the CMA dysfunction pheno-
type of different neurodegenerative diseases may not be
completely identical since the expression levels of CMA
markers, LAMP2A and Hsc70, and CMA activity itself,
vary among different diseases. For example, CMA activity
appeared to be up-regulated in HD in one study [45],
and therefore, the increasing CMA activity may be a
compensatory mechanism to promote clearance of
Htt by CMA [56]. In contrast, a decrease in CMA ac-
tivity has been reported in other neurodegenerative
diseases, including PD and AD [44,57]. But even
among this group of diseases, there may be differ-
ences in changes occurring along the CMA pathway.
Alvarez-Erviti et al. found that the expression levels of
LAMP2A and Hsc70 are significantly reduced in the sub-
stantia nigra pars compacta and amygdala of PD brains
compared with age-matched AD and control brain sam-
ples [44].
Pathogenic variants of CMA substrate protein in
neurodegenerative diseases
Currently, several proteins involved in neurodegenera-
tive diseases have been reported as CMA substrates
(Table 1). The reported effects of these mutant variants
on CMA functions are summarized therein. There is no
doubt that the list of CMA-related pathogenic proteins
will grow with future research.
Summary and perspective
In summary, the identification of selective degradation
of proteins relevant to neuronal survival and stress viaCMA has expanded the repertoire of cellular mecha-
nisms by which CMA may be involved in the pathogen-
esis of neurodegeneration. The methods currently available
to study CMA allow for measurement of the steps of the
entire CMA process and flux through these steps [62,63].
Combination of different types of approaches, including
genetic method and CMA-modulating drug, should be
useful to reveal additional mechanisms by which CMA
dysfunction may trigger pathogenesis and enable the
dissection of the specific steps of CMA which are dys-
functional in the pathogenic process. Agents capable
of modulating lysosomal activity, for example, neutral-
izers of lysosomal pH like chloroquine, are currently
tested in anti-cancer clinical trials [64,65]. Interven-
tions to prevent CMA blockage and improve CMA
throughput, particularly in the brain, may have thera-
peutic value in the treatment of neurodegenerative dis-
eases and are therefore worth evaluating. In addition, a
recent study has revealed a decrease in the level of
Hsc70 in lymphomonocytes isolated from PD patients,
suggesting that CMA associated proteins and/or cargoes
may be explored as new biomarker(s) for neurodegenera-
tion [66].
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